Tag: Bispecific ADCs
B7-H3 Antibody-Drug Conjugates Gain Momentum as Frontline Standards Shift Across Solid...
B7-H3 Antibody-Drug Conjugates Gain Momentum as Frontline Standards Shift Across Solid Tumors
Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer:...
Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer: Insights from ASCO 2026
The Most Interesting Activity in ADC Development is no Longer Happening...
The Most Interesting Activity in ADC Development is no Longer Happening in Traditional Formats
Developing ‘Next-Gen’ Therapeutics: a First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC
Bispecific ADCs (bsADCs) are positioned as an emerging, next-generation, class of therapeutics, combining the dual-targeting capabilities of bispecific antibodies (bsAbs) with the potent cytotoxicity of antibody-drug conjugates (ADCs). The resulting bsADC offers improved efficacy and safety for the treatment of heterogeneous solid tumors.
